Uromed
This article was originally published in The Gray Sheet
Executive Summary
Firm's CaverMap prostate surgical aid, AlloSling tissue graft, and line of brachytherapy introduction insertion needles are exhibited at the recent American Urological Association annual meeting in San Diego. CaverMap, intended to assist in impotence prophylaxis during prostate surgery, assists the location and stimulation of cavernosal nerves. AlloSling, a pre-harvested natural tissue graft material, is used with the Needham, Massachusetts firm's 510(k) cleared Access instruments in female incontinence-correcting sling procdures. The radioactive brachytherapy introduction needles, manufactured by a third party, are intended to pave the way for the third-quarter launch of Uromed's I125 prostate cancer therapy device
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.